DEF: Bausch Health Sets May 19th Annual Meeting

Bausch Health Companies Inc. has announced its 2026 Annual Meeting of Shareholders will be held virtually on May 19, 2026, to elect directors, approve executive compensation, and appoint auditors.

Summary

• Bausch Health Companies Inc. is holding its 2026 Annual Meeting of Shareholders on Tuesday, May 19, 2026, at 9:00 a.m. Eastern Daylight Time.
• The meeting will be conducted virtually via a live internet webcast.
• Shareholders of record as of March 20, 2026, are entitled to vote.
• The primary purposes of the meeting include the election of ten directors, an advisory vote on executive compensation for 2025, and the appointment of PricewaterhouseCoopers LLP (PwC) as the company's auditor.
• The company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, is available on its website.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it details standard corporate governance procedures and director nominations, with a strong emphasis on shareholder engagement and alignment of executive compensation with performance.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• Nine of the ten director nominees are considered independent.
• The Board has a clear structure with a Non-Executive Chairperson.
• The company has a comprehensive Code of Conduct and ethical business practices.
• The company has established share ownership guidelines for directors and executive officers.
• The Talent and Compensation Committee actively engages with shareholders regarding executive compensation.
• The company's 2025 Annual Meeting saw approximately 94% shareholder approval for its executive compensation program.
• PwC is recommended for reappointment as auditor, indicating a stable relationship with the audit firm.

Negatives

• One director nominee, Thomas J. Appio, is not independent.
• Some directors are still working towards meeting the company's share ownership guidelines.
• The company's 2025 revenue growth of 7% is noted, but specific financial performance details beyond this are not the primary focus of this proxy statement.
• The company's pay ratio of 401:1 (CEO to median employee) is high, though this is a common metric in executive compensation disclosures.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, as detailed in the company's Form 10-K and other SEC filings.
• The company's business and operations are subject to various risks, including those related to the pharmaceutical industry, regulatory environments, and competition, as outlined in its risk factors.

Future Outlook

The filing does not provide specific forward-looking financial guidance but focuses on the upcoming annual meeting agenda and corporate governance matters. The company's commitment to aligning executive compensation with long-term business performance and shareholder value creation is highlighted.

Management Comments

• "YOUR VOTE IS IMPORTANT"
• "We are providing you with this Proxy Statement and related materials in connection with the solicitation of proxies by our management."
• "We believe that these changes provide complementary perspectives and strengthen its ability to effectively oversee the Companys operations and drive long-term value creation."
• "The Board is committed to sound and effective corporate governance practices with the goal of ensuring the Companys financial strength and overall business success."
• "We believe that these favorable results indicate strong support for continuing our current executive compensation program."

Industry Context

StockSavvy.ai notes that Bausch Health's proxy statement reflects standard corporate governance practices for a publicly traded pharmaceutical company, including director elections, executive compensation review, and auditor ratification. The emphasis on independent directors and robust compensation policies aligns with industry best practices for transparency and accountability.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a Director Appointment and Nomination Agreement with Carl C. Icahn, Brett M. Icahn, Steven D. Miller, Icahn Partners, Icahn Master, Icahn Enterprises GP, Icahn Enterprises Holdings, IPH, Icahn Capital, Icahn Onshore, Icahn Offshore, and Beckton (collectively, the Icahn Group) on February 24, 2021. This agreement was terminated on August 14, 2025, and the Icahn Designees resigned from the Board.

Stakeholder Impact

• Shareholders: The meeting provides an opportunity for shareholders to vote on director elections, executive compensation, and auditor appointments, influencing corporate governance and executive accountability.
• Employees: The company's commitment to ethical conduct, employee growth, and well-being is outlined, with specific metrics like Lost Time Incident Rate provided.
• Management: Executive compensation is tied to company performance and shareholder value, with clear guidelines and oversight from the Talent and Compensation Committee.

Next Steps

• Shareholders are encouraged to vote their shares prior to the meeting.
• The company will hold its Annual Meeting of Shareholders on May 19, 2026.
• The Board will consider shareholder feedback on executive compensation.
• PwC will continue as the company's auditor until the close of the 2027 Annual Meeting of Shareholders.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting, detailing director nominations, executive compensation, and auditor appointments. While it outlines governance practices and management's approach to compensation, it does not contain new material financial information or strategic shifts that would warrant a buy or sell recommendation. The company's performance in 2025 showed revenue growth and debt reduction, but the proxy statement's focus is on governance rather than forward-looking financial guidance.

Keywords

Bausch Health, Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Auditor Appointment, Corporate Governance, Shareholder Vote